AGENUS INC
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
AGEN | NDAQ
Overview
Corporate Details
- ISIN(s):
- US00847G8042
- LEI:
- Country:
- United States of America
- Address:
- 3 FORBES ROAD, 2421 LEXINGTON
- Website:
- https://agenusbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Agenus Inc. is a clinical-stage immuno-oncology company that discovers, develops, and manufactures therapeutics designed to harness the body's immune system to combat cancer. The company's vision is to expand the patient population benefiting from immuno-oncology through combination approaches. Its portfolio includes a broad repertoire of antibody therapeutics, adoptive cell therapies (via its subsidiary MiNK Therapeutics), and vaccine adjuvants (via its subsidiary SaponiQx). A key focus is its next-generation CTLA-4 antibody, botensilimab, which is engineered for enhanced potency and tolerability to treat difficult-to-treat solid tumors. Agenus utilizes strategic partnerships with industry leaders to accelerate development and support its pipeline.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all AGENUS INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for AGENUS INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for AGENUS INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
